Brief: Lundbeck Announces Positive Results From Phase III Pivotal Trial (Sunrise) Of Vyepti In Migraine Prevention

H Lundbeck A/S

31/10/2024 14:07

Oct 31 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * ANNOUNCES POSITIVE RESULTS FROM PHASE III PIVOTAL TRIAL (SUNRISE) OF VYEPTI® (EPTINEZUMAB)
IN
MIGRAINE PREVENTION
    * VYEPTI CONFIRMS EFFICACY IN NEW PHASE III PIVOTAL SUNRISE TRIAL, MEETING PRIMARY ENDPOINT
WITH
STATISTICALLY SIGNIFICANT REDUCTIONS IN MEAN MONTHLY MIGRAINE DAYS COMPARED WITH PLACEBO
    * VYEPTI MET ALL KEY SECONDARY EFFICACY ENDPOINTS IN SUNRISE TRIAL, AND TREATMENT WAS
GENERALLY
WELL TOLERATED
    * BEGINNING DAY 1 AFTER INFUSION, VYEPTI® LEAD TO STATISTICALLY SIGNIFICANT REDUCTIONS IN
RISK OF
EXPERIENCING MIGRAINE COMPARED TO PLACEBO
    * PLANS TO INITIATE DISCUSSIONS WITH RELEVANT REGULATORY AUTHORITIES WITH AIM OF MAKING
VYEPTI
AVAILABLE FOR PEOPLE SUFFERING FROM MIGRAINE ACROSS ASIA

Source text:  ID:nWkr47xGTj 
Further company coverage:  HLUNb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))